{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:49Z","timestamp":1787020189072,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glomerular lipidosis is a rare histological feature presenting the extensive glomerular accumulation of lipids with or without histiocytic infiltration, which develops under various conditions. Among its various etiologies, macrophage activation syndrome (MAS) is a condition reported to be associated with histiocytic glomerular lipidosis. Here we describe the first case of glomerular lipidosis observed in a renal allograft that histologically mimicked histiocytic glomerulopathy owing to MAS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 42-year-old man underwent successful living-donor kidney transplantation. However, middle-grade proteinuria and increased serum triglyceride levels indicative of type V hyperlipidemia developed rapidly thereafter. An allograft biopsy performed 6\u00a0months after the transplantation showed extensive glomerular infiltration of CD68\n                      <jats:sup>+<\/jats:sup>\n                      foam cells (histiocytes) intermingled with many CD3\n                      <jats:sup>+<\/jats:sup>\n                      T-cells (predominantly CD8\n                      <jats:sup>+<\/jats:sup>\n                      cells). Furthermore, frequent contact between glomerular T-cells and histiocytes, and the existence of activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      cells (CD8\n                      <jats:sup>+<\/jats:sup>\n                      , HLA-DR\n                      <jats:sup>+<\/jats:sup>\n                      cells) were observed by double immunostaining. There was no clinicopathological data suggesting lipoprotein glomerulopathy or lecithin cholesterol acyltransferase deficiency, both of which are well-known causes of glomerular lipidosis. The histological findings were relatively similar to those of histiocytic glomerulopathy caused by MAS. As systemic manifestations of MAS, such as fever, pancytopenia, coagulation abnormalities, hyperferritinemia, increased liver enzyme levels, hepatosplenomegaly, and lymphadenopathy were minimal, this patient was clinicopathologically diagnosed as having renal-limited MAS. Although optimal treatment strategies for MAS in kidney transplant patients remains unclear, we strengthened lipid-lowering therapy using pemafibrate, without modifying the amount of immunosuppressants. Serum triglyceride levels were normalized with this treatment; however, the patient\u2019s extensive proteinuria and renal dysfunction did not improve. Biopsy analysis at 1\u00a0year after the transplantation demonstrated the disappearance of glomerular foamy changes, but the number of glomerular infiltrating cells remained similar.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      To our knowledge, this is the first reported case of glomerular lipidosis in a transplanted kidney. Increased interaction-activation of histiocytes (macrophages) and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cells, the key pathogenic feature of MAS, was observed in the glomeruli of this patient, who did not demonstrate overt systemic manifestations, suggesting a pathological condition of renal-limited MAS. The clinical effects of triglyceride-lowering therapy were limited, suggesting that hypertriglyceridemia was not the cause of but rather may be a consequence of renal-limited MAS.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03380-2","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T16:43:08Z","timestamp":1699375388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Glomerular lipidosis as a feature of renal-limited macrophage activation syndrome in a transplanted kidney: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Kentaro","family":"Sugisaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Okihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"issue":"3","key":"3380_CR1","first-page":"245","volume":"24","author":"M Eom","year":"2015","unstructured":"Eom M, Hudkins KL, Alpers CE. Foam cells and the pathogenesis of kidney disease. Curr Opin Nephrol Hypertens. 2015;24(3):245\u201351.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"7","key":"3380_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0046-8177(87)80238-1","volume":"18","author":"T Faraggiana","year":"1987","unstructured":"Faraggiana T, Churg J. Renal lipidoses: a review. Hum Pathol. 1987;18(7):661\u201379.","journal-title":"Hum Pathol"},{"issue":"2","key":"3380_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.kint.2019.10.031","volume":"97","author":"T Saito","year":"2020","unstructured":"Saito T, Matsunaga A, Fukunaga M, Nagahama K, Hara S, Muso E. Apolipoprotein E-related glomerular disorders. Kidney Int. 2020;97(2):279\u201388.","journal-title":"Kidney Int"},{"issue":"2","key":"3380_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10157-013-0882-9","volume":"18","author":"H Sato","year":"2014","unstructured":"Sato H, Takahashi N, Sato E, Kisu K, Ito S, Saito T. Pathology of glomerular lipidosis. Clin Exp Nephrol. 2014;18(2):194\u20136.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"3380_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.ajkd.2015.07.040","volume":"67","author":"A Kaur","year":"2016","unstructured":"Kaur A, Sethi S. Histiocytic and nonhistiocytic glomerular lesions: foam cells and their mimickers. Am J Kidney Dis. 2016;67(2):329\u201336.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3380_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","volume":"22","author":"LA Henderson","year":"2020","unstructured":"Henderson LA, Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Paediatr Drugs. 2020;22(1):29\u201344.","journal-title":"Paediatr Drugs"},{"key":"3380_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jpeds.2017.06.005","volume":"189","author":"F Minoia","year":"2017","unstructured":"Minoia F, Bovis F, Davi S, Insalaco A, Lehmberg K, Shenoi S, et al. Development and initial validation of the macrophage activation syndrome\/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome. J Pediatr. 2017;189:72-78.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.005.","journal-title":"J Pediatr"},{"issue":"5","key":"3380_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.blre.2007.05.001","volume":"21","author":"GE Janka","year":"2007","unstructured":"Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245\u201353.","journal-title":"Blood Rev"},{"issue":"3","key":"3380_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American college of rheumatology\/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2016;68(3):566\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3380_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735\u201343.","journal-title":"Blood"},{"issue":"9","key":"3380_CR11","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"3380_CR12","doi-asserted-by":"publisher","first-page":"796121","DOI":"10.3389\/fmed.2022.796121","volume":"9","author":"D Roccatello","year":"2022","unstructured":"Roccatello D, Sciascia S, Barreca A, Naretto C, Alpa M, Quattrocchio G, et al. Renal involvement as a unique manifestation of hemophagocytic syndrome. Front Med (Lausanne). 2022;9:796121. https:\/\/doi.org\/10.3389\/fmed.2022.796121.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3380_CR13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.ajkd.2015.11.017","volume":"67","author":"D Santoriello","year":"2016","unstructured":"Santoriello D, Hogan J, D\u2019Agati VD. Hemophagocytic syndrome with histiocytic glomerulopathy and intraglomerular hemophagocytosis. Am J Kidney Dis. 2016;67(6):978\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3380_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/01.TP.0000107285.86939.37","volume":"77","author":"A Karras","year":"2004","unstructured":"Karras A, Thervet E, Legendre C and Groupe Cooperatif de transplantation d\u2019Ile de France. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation. 2004;77(2):238\u201343.","journal-title":"Transplantation"},{"issue":"3","key":"3380_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5","volume":"44","author":"RJ Risdall","year":"1979","unstructured":"Risdall RJ, McKenna RW, Nesbit ME, Krivit W, Balfour HHJ, Simmons RL, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 1979;44(3):993\u20131002.","journal-title":"Cancer"},{"issue":"12","key":"3380_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2337\/diab.39.12.1569","volume":"39","author":"KR Feingold","year":"1990","unstructured":"Feingold KR, Soued M, Adi S, Staprans I, Shigenaga J, Doerrler W, et al. Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes. 1990;39(12):1569\u201374.","journal-title":"Diabetes"},{"key":"3380_CR17","doi-asserted-by":"crossref","unstructured":"Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol. Educ Program. 2013;605\u2013611.","DOI":"10.1182\/asheducation-2013.1.605"},{"issue":"3","key":"3380_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/cei.13111","volume":"192","author":"MF Saja","year":"2018","unstructured":"Saja MF, Cook HT, Ruseva MM, Szajna M, Pickering MC, Woollard KJ, et al. A triglyceride-rich lipoprotein environment exacerbates renal injury in the accelerated nephrotoxic nephritis model. Clin Exp Immunol. 2018;192(3):337\u201347.","journal-title":"Clin Exp Immunol"},{"issue":"40","key":"3380_CR19","doi-asserted-by":"publisher","first-page":"25573","DOI":"10.1074\/jbc.273.40.25573","volume":"273","author":"G Chinetti","year":"1998","unstructured":"Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors \u03b1 and \u0433 induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273(40):25573\u201380.","journal-title":"J Biol Chem"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03380-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T16:43:58Z","timestamp":1699375438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03380-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03380-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of clinical information, including symptoms, laboratory data, histological findings, and any accompanying images as a case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}